Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ClinicalTrials.gov ID: NCT03206047

Public ClinicalTrials.gov record NCT03206047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer

Study identification

NCT ID: NCT03206047
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 12 participants

Conditions and interventions

Conditions

Interventions

Atezolizumab Drug
DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Biological
Guadecitabine Drug
Laboratory Biomarker Analysis Other
Poly ICLC Drug

Drug · Biological · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 7, 2017
Primary completion: Nov 9, 2020
Completion: Nov 9, 2020
Last update posted: Mar 12, 2025

2017 – 2020

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Banner University Medical Center - Tucson	Tucson	Arizona	85719	—
University of Arizona Cancer Center-North Campus	Tucson	Arizona	85719	—
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
University of California Davis Comprehensive Cancer Center	Sacramento	California	95817	—
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
UC Comprehensive Cancer Center at Silver Cross	New Lenox	Illinois	60451	—
University of Chicago Medicine-Orland Park	Orland Park	Illinois	60462	—
University of Kansas Clinical Research Center	Fairway	Kansas	66205	—
Nebraska Medicine-Village Pointe	Omaha	Nebraska	68118	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	—
Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03206047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 12, 2025 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03206047 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →